Friday 6 November 2026 Export BEAM’s income statement to Excel — free account

Beam Therapeutics Inc.

Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024.

Revenue: −96.8%
EPS: −16.7%
Free cash flow: −29.5%

Quarter to September 2026, against a year earlier

26.59 0.72 +2.78%

Follow BEAM

Alert me

Market cap: $2.7B
P/E: 0.0×
Fwd P/E: −6.2×
Dividend yield: —
F-score: 4/9
Altman Z: 5.41
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Sold, $m 19.74

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	5	1	1	5	—	3	1	—	—	2	—

Insider Ownership 9.04%

Capital & Financial Ratios $m

Size

Market Cap 2,680.00

Revenue ttm 146.64

Net income ttm (108.35)

Free cash flow ttm (398.24)

Net debt Q (943.51)

Valuation

P/E 0.00

Forward P/E (6.16)

Price / sales 18.63

Forward P/S Powerpack

Price / FCF 0.00

Price / book 2.87

Financial health

Current ratio Q 13.00

Debt / equity Q 0.11

Interest coverage Q (8.53)

Growth

Revenue growth Q −96.83%

Operating income growth Q −11.44%

EPS, this year −470.30%

EPS, next year A −12.52%

Revenue, next year A −61.92%

EPS, past 5 yrs —

EPS, next 5 yrs A −1.61%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 21.63%

10-year low 10-year high

P/B against its own 10 years 44.88%

10-year low 10-year high

EV/Sales against its own 10 years 30.48%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1,190	851	1,245	1,044
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	1,211	878	1,269	1,067

	2023	2024	2025	Q'26
Payables	2	4	10	20
ST’ Debt	—	—	—	—
Other	11	8	10	6
	206	182	97	82

Compound Annual Growth %

	10y	5y	3y
Sales	—	466.27%	31.88%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	38.21%	19.07%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −1.17 Actual −1.28

−1.46 −1.07 −0.69 −0.31 0.08

Q4 FY25 Beat +1.03

Q1 FY26 Miss −0.04

Q2 FY26 Miss −0.18

Q3 FY26 Miss −0.11

Q4 FY26 — Feb 23

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q4 FY25	−1.13	−0.10	Beat by 1.03
Q1 FY26	−0.87	−0.91	Miss by 0.04
Q2 FY26	−1.00	−1.18	Miss by 0.18
Q3 FY26	−1.17	−1.28	Miss by 0.11
Q4 FY26	−1.25	—	Reports 23 February 2027

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.91)	(1.18)	(1.28)	—	—
’25	(1.24)	(1.00)	(1.10)	2.33	(0.81)
’24	(1.21)	(1.11)	(1.17)	(1.09)	(4.58)
’23	(1.33)	(1.08)	(1.22)	1.73	(1.72)
’22	(1.01)	(1.02)	(1.56)	(0.54)	(4.13)
’21	(3.35)	(1.23)	(0.42)	(0.95)	(5.77)
’20	(1.03)	(0.69)	(0.69)	(1.69)	(4.19)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	32	0	0	—	—
’25	7	8	10	114	140
’24	7	12	14	30	64
’23	24	20	17	316	378
’22	8	17	16	20	61
’21	0	0	1	51	52
’20	0	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(129)	(66)	(111)	—	—
’25	(104)	(76)	(81)	(83)	(345)
’24	(100)	(83)	(88)	(76)	(347)
’23	(110)	(85)	(90)	135	(149)
’22	218	(52)	(74)	(69)	23
’21	(39)	(33)	3	2	(66)
’20	(27)	(23)	(21)	(24)	(96)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(131)	(69)	(112)	—	—
’25	(107)	(80)	(86)	(87)	(360)
’24	(102)	(85)	(90)	(79)	(356)
’23	(116)	(101)	(98)	131	(183)
’22	211	(74)	(86)	(77)	(26)
’21	(50)	(49)	(3)	(12)	(113)
’20	(30)	(25)	(24)	(32)	(112)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Sep ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	—	0	0	52	61	378	64	140	147		+345.0%	53	61	103	(9.7%)
	Gross margin, %	—	0.00	0.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00		+100.0 pt	Powerpack Beam Therapeutics Inc.’s next three years, line by line Analysts expect revenue to shrink 9.7% a year to 2028 — slower than the 345.0% of the last 6 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	—	(8)	(117)	(78)	(195)	(371)	(260)	(131)	(377)	(80)	(108)		+33.3%
	EBT margin, %	—	0.00	0.00	(435,144.44)	(810,800.00)	(714.91)	(427.08)	(34.73)	(593.06)	(57.24)	(73.89)		(57.2) pt
	Net income	—	0	(117)	(78)	(195)	(371)	(289)	(133)	(377)	(80)	(108)		n/m
Per share, $
Per share, $	Revenue	—	0.00	0.00	0.00	0.00	0.81	0.87	4.90	0.77	1.41	1.40		n/m
	Earnings	—	(0.19)	(40.34)	(14.05)	(4.19)	(5.77)	(4.13)	(1.72)	(4.58)	(0.81)	(1.00)		+19.9%
	Cash flow	—	(0.05)	(7.01)	(11.11)	(2.05)	(1.03)	0.32	(1.93)	(4.22)	(3.49)	(3.71)		+68.2%
	Capex	—	0.00	(4.53)	(1.93)	(0.35)	(0.73)	(0.70)	(0.44)	(0.11)	(0.15)	(0.09)		n/m
	Free cash flow	—	(0.05)	(11.55)	(13.04)	(2.40)	(1.76)	(0.38)	(2.37)	(4.33)	(3.64)	(3.80)		+69.1%
	Book value	—	(0.08)	(40.57)	(31.04)	5.25	12.87	10.48	12.72	8.91	12.52	9.10		n/m
	Shares, m	—	50	3	6	47	64	70	77	82	99	103		+9.0%
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	—	—	—	0.00	158,970.77	98.73	42.89	5.60	32.14	19.62	18.63		22,738.5
	P/B	—	—	—	0.00	15.54	6.19	3.56	2.16	2.78	2.21	2.87		4.6
	EV/Sales	—	—	—	0.00	150,692.81	82.76	27.98	2.87	21.28	11.86	12.20		21,548.5
	EV/FCF	—	—	—	(0.65)	(32.26)	(37.94)	(64.52)	(5.94)	(3.79)	(4.60)	(4.49)		(21.4)
Cash, $m
Cash, $m	Operating cash flow	—	(3)	(20)	(72)	(96)	(66)	23	(149)	(347)	(345)	(389)		+83.3%
	Capex	—	0	(13)	(13)	(16)	(47)	(49)	(34)	(9)	(15)	(10)		+60.1%
	Free cash flow	—	(3)	(33)	(85)	(112)	(113)	(26)	(183)	(356)	(360)	(398)		+84.3%
Balance, $m
Balance, $m	Working capital	—	(5)	123	65	206	1,060	869	1,005	696	1,172	985		n/m
	Net debt	—	(1)	(146)	(92)	(300)	(966)	(1,078)	(1,190)	(851)	(1,245)	(944)		+143.7%
	Shareholders’ equity	—	(4)	(117)	(201)	246	827	733	981	734	1,238	953		n/m
Returns, %
Returns, %	ROA	—	(11.46)	(139.80)	(56.35)	(64.45)	(38.49)	(20.53)	(9.46)	(29.39)	(6.19)	(8.40)		+5.3 pt
	ROIC	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(2,676.86)		0.0 pt
	ROE	—	15.38	184.70	57.17	(881.16)	(69.13)	(37.06)	(15.46)	(43.94)	(8.11)	(11.29)		(23.5) pt
People
People	Employees	—	—	112	118	181	341	507	436	483	511	—		+24.2%
	Revenue/emp, $m	—	—	0.00	0.00	0.00	0.15	0.12	0.87	0.13	0.27	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
VRDN Viridian Therapeutics, Inc.	$3.2B	— (loss-making)	— (loss-making)	−63.51% (below 0%: shrinking)	n/m	−9.92% (below 0%: shrinking)	100.00%	(401.82%)	Compare
TLX Telix Pharmaceuticals Limited	$3.2B	—	—	—	—	−44.78% (below 0%: shrinking)	—	—	Compare
IDYA IDEAYA Biosciences, Inc.	$3.0B	— (loss-making)	— (loss-making)	−95.07% (below 0%: shrinking)	n/m	−165.94% (below 0%: shrinking)	100.00%	(1,343.80%)	Compare
BEAM Beam Therapeutics Inc.	$2.7B	— (loss-making)	— (loss-making)	−96.83% (below 0%: shrinking)	n/m	−29.45% (below 0%: shrinking)	100.00%	(46,033.22%)
ZLAB Zai Lab Limited Unsponsored ADR	$2.6B	— (loss-making)	— (loss-making)	−6.79% (below 0%: shrinking)	n/m	−95.46% (below 0%: shrinking)	0.00%	(58.20%)	Compare
XNCR Xencor, Inc.	$2.5B	— (loss-making)	— (loss-making)	+17.46% (above 0%: growing)	n/m	−52.91% (below 0%: shrinking)	100.00%	(72.37%)	Compare
RCUS Arcus Biosciences, Inc.	$2.5B	— (loss-making)	— (loss-making)	−65.38% (below 0%: shrinking)	n/m	+9.28% (above 0%: growing)	100.00%	(1,455.56%)	Compare
MBX MBX Biosciences, Inc.	$2.3B	— (loss-making)	—	—	n/m	−29.67% (below 0%: shrinking)	—	0.00%	Compare
NAMS NewAmsterdam Pharma Company N.V.	$2.3B	— (loss-making)	— (loss-making)	+5,406.90% (above 0%: growing)	n/m	−21.76% (below 0%: shrinking)	100.00%	(230.58%)	Compare
Median of peers	$2.5B	—	—	−35.15%	—	−37.22%	100.00%	(230.58%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 17 April 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2025	5.82m	8.40m	33.95
2024	6.41m	7.27m	132.27
2023	6.28m	2.83m	145.17
2022	9.50m	(13.94m)	208.59
2021	13.91m	17.02m	425.01

Ownership

Directors and executive officers, together 3.80%

FMR LLC and affiliates 12.70%

Ark Investment Management LLC and affiliates 12.40%

Farallon Capital Partners LP and affiliates 10.10%

The Vanguard Group 7.60%

BlackRock, Inc. 7.50%

State Street Corporation 5.20%

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Beam Therapeutics Inc. (BEAM) Latest News

4 Nov

Impact 3 · 9:00 AM · GlobeNewswire

Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting

3 Nov

Impact 4 · 7:00 AM · GlobeNewswire

Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio

29 Oct

Impact 4 · 6:14 AM · Simply Wall St.

Why Beam Therapeutics Stock Is Up 15.6% And What's Next

Impact 3 · 3:50 AM · Zacks

Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?

27 Oct

Impact 4 · 3:21 PM · Stocktwits

BEAM Stock Climbs On First Look At One-Time GSDIa Gene Fix; H.C. Wainwright Sees Further 200% Upside

Impact 4 · 11:05 AM · MarketBeat

Beam Therapeutics Reports Early BEAM-301 Gains in GSD1a Fasting Tolerance

Impact 4 · 7:00 AM · GlobeNewswire

Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress

17 Oct

Impact 4 · 9:20 PM · The Motley Fool

Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?

13 Oct

Impact 4 · 7:00 AM · GlobeNewswire

Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress

30 Sep

Impact 3 · 9:23 PM · Simply Wall St.

Will IP Theft Allegations Against YolTech and Serapha Bio Change Beam Therapeutics' (BEAM) Narrative

29 Sep

Impact 4 · 2:34 PM · biopharmadive.com

Beam sues 2 biotechs, alleging theft of base editing trade secrets

28 Sep

Impact 4 · 5:02 PM · Barchart

As Claude Enters the Gene-Editing Arena, There’s Still a Long-Term Case for BEAM Stock

23 Sep

Impact 3 · 9:14 PM · Simply Wall St.

Beam Therapeutics (BEAM) Stock Could Trade At A Premium As Gene Editing Interest Grows

Impact 3 · 8:22 AM · 24/7 Wall St.

CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon

10 Sep

Impact 4 · 7:33 PM

Beam Therapeutics (BEAM) Restored AAT Levels. Can BEAM-302 Deliver Clinical Benefit?

8 Sep

Impact 4 · 9:22 AM

Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment

Impact 3 · 6:00 AM

Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026

5 Aug

Impact 3 · 11:10 AM

BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus

4 Aug

Impact 4 · 7:00 AM

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

Impact 3 · 8:25 AM

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates

27 Jul

Impact 4 · 4:08 PM

Scribe’s Genetic Editing Aims to Prevent Heart Attacks

23 Jul

Impact 3 · 7:00 AM

Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026

9 Jul

Impact 3 · 4:14 PM

Beam Therapeutics (BEAM) Faces New AATD Rival PM647 Ruling What Does It Signal Strategically?

8 Jul

Impact 4 · 12:47 PM · Stocktwits

PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug

Impact 4 · 6:05 AM · The Motley Fool

A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics

Impact 3 · 8:00 AM

Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics

19 Jun

Impact 4 · 10:35 AM

BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria

18 Jun

Impact 4 · 7:00 AM

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration

16 Jun

Impact 3 · 8:53 AM

Is Beam Therapeutics Inc. (BEAM) One of the Best Genomics Stocks to Buy According to Analysts?

27 May

Impact 4 · 11:15 PM · Simply Wall St.

Beam Therapeutics (BEAM) Is Up 17.6% After Advancing BEAM-302 Toward Accelerated Approval in AATD

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Beam Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 17 April 2026

Chief executive’s pay

Ownership

Beam Therapeutics Inc. (BEAM) Latest News

4 Nov

3 Nov

29 Oct

27 Oct

17 Oct

13 Oct

30 Sep

29 Sep

28 Sep

23 Sep

10 Sep

8 Sep

5 Aug

4 Aug

27 Jul

23 Jul

9 Jul

8 Jul

19 Jun

18 Jun

16 Jun

27 May

BEAM metrics, ten years each

Stockrow Weekly